We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. IL-23 inhibitors were associated with the lowest ...

Researchers determine the clinical and demographic risk factors of paradoxical eczema as well as the overall incidence and biologic-class-specific risk factors and incidence of paradoxical eczema in ...

Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the treatment of plaque psoriasis. We conducted a phase 3, double-blind, randomized, ...

People mounting an immune attack on interleukin-23 (IL-23) were prone to severe opportunistic infections rarely seen in the clinic, a study found. After investigations showed that anti-IL-23 ...

Please provide your email address to receive an email when new articles are posted on . Novel interleukin-23 inhibitor icotrokinra improved on placebo in adolescent psoriasis. Icotrokinra yielded more ...

Authors describe 3 patients with cancer who were given interleukin-23 (IL-23) inhibitors for psoriasis or immune-related psoriasis. Interleukin-23 (IL-23) inhibitors may be a safe option to treat ...

Data point to the potential of JNJ-2113 as a first-in-class drug candidate in multiple IL-23 driven-diseases Highlights of the data presented on JNJ-2113 include the following: JNJ-2113 is a ...

Mirikizumab, a p19-directed antibody against interleukin-23, showed efficacy in the treatment of ulcerative colitis in a phase 2 trial. We conducted two phase 3, randomized, double-blind, ...